pharma · Adenocarcinoma of Lung · Primary Sjögren's Syndrome
Peking University Biologics
Peking University People's Hospital
Peking University People's is a pharma organization headquartered in CN. Primary therapeutic focus areas include Adenocarcinoma of Lung, Primary Sjögren's Syndrome. NovaPharmaNews links 2 clinical program(s), 0 drug prof
CN HQ
2018 Founded
8 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 8
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Furmonertinib
Phase 2 · small molecule · Adenocarcinoma of Lung
Furmonertinib for Adenocarcinoma of Lung is a Phase 2 program (small_molecule) at Peking University People's Hospital with 1 ClinicalTrials.gov record(s).
Internal code Y-2021 AST/zd-0105
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Peking University People's Hospital
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Adenocarcinoma of Lung
- Status
- active
- Trials
- 1